The c-Fes protein tyrosine kinase as a potential anti-angiogenic target in cancer

Frontiers in Bioscience

Volumn 16, Issue 3, 2011, Pages 1024-1035

  Kanda, Shigeru ^a,c   Miyata, Yasuyoshi ^b  

^a Department of Molecular Microbiology and Immunology   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Angiopoietin; C Fes; Endothelial Cell; FGF; IL 8; Review; SDF 1alpha; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; PROTEIN KINASE FES; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REVIEW;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; CHEMOKINE CXCL12; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTORS; HUMANS; INTERLEUKIN-8; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-FES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79955009114     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3732     Document Type: Article

References (118)

1. J. Folkman: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1, 27-31 (1995)
2. P. Carmeliet and R.K. Jain: Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000)
3. L. Beck Jr and P.A. D'Amore: Vascular development: cellular and molecular regulation. FASEB J 11, 365-373 (1997) (Pubitemid 27193941)
4. S. Klein, M. Roghani and D.B. Rifkin: Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. EXS 79, 159-192 (1997)
5. N. Ferrara: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77, 527-543 (1999) (Pubitemid 29426311)
6. E.M. Rosen, K. Lamszus, J. Laterra, P.J. Polverini, J.S. Rubin and I.D. Goldberg: HGF/SF in angiogenesis. Ciba Found Symp 212, 215-226 (1997)
7. W.S. Shim, I.A. Ho and P.E. Wong: Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5, 655-665 (2007) (Pubitemid 47105484)
8. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera and B. Bilanges: The emerging mechanisms of isoformspecific PI3K signalling. Nat Rev Mol Cell Biol 11, 329-341 (2010)
9. K.B. Reddy, S.M. Nabha and N. Atanaskova: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22, 395-403 (2003) (Pubitemid 36791895)
10. J.M. Summy and G.E. Gallick: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22, 337-358 (2003) (Pubitemid 36791891)
11. S. Kanda, Y. Miyata, H. Kanetake and T.E. Smithgall: Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review). Int J Mol Med 20, 113-121 (2007)
12. N. Ferrara, H.-P. Gerber and J. LeCouter: The biology of VEGF and its receptor. Nature Med 9, 669-676 (2003)
13. R.K. Jain: Molecular regulation of vessel maturation. Nat Med 9, 685-693 (2003) (Pubitemid 36749217)
14. M. Shibuya and L. Claesson-Welsh: Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312, 549-560 (2006) (Pubitemid 43290332)
15. H. Gerhardt, M. Golding, M. Fruttiger, C. Ruhrberg, A. Lundkvist, A. Abramsson, M. Jeltsch, C. Mitchell, K. Alitalo, D. Shima and C. Betsholtz: VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161, 1163-1177 (2003) (Pubitemid 36870177)
16. M. Hellström, L.K. Phng, J.J. Hofmann, E. Wallgard, L. Coultas, P. Lindblom, J. Alva, A.K. Nilsson, L. Karlsson, N. Gaiano, K. Yoon, J. Rossant, M.L. Iruela-Arispe, M. Kalén, H. Gerhardt and C. Betsholtz: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776-780 (2007) (Pubitemid 46279716)
17. L.S. Harrington, R.C. Sainson, C.K. Williams, J.M. Taylor, W. Shi, J.L. Li and A.L. Harris: Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res 75, 144-154 (2008) (Pubitemid 351249857)
18. S. Suchting, C. Freitas, F. le Noble, R. Benedito, C. Bréant, A. Duarte and A. Eichmann: The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A 104, 3225-3230 (2007) (Pubitemid 46364141)
19. R. Benedito, C. Roca, I. Sörensen, S. Adams, A. Gossler, M. Fruttiger and R.H. Adams: The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137, 1124-1135 (2009)
20. A.F. Siekmann and N.D. Lawson: Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature 445, 781-784 (2007) (Pubitemid 46279717)
21. T. Tammela, G. Zarkada, E. Wallgard, A. Murtomäki, S. Suchting, M. Wirzenius, M. Waltari, M. Hellström, T. Schomber, R. Peltonen, C. Freitas, A. Duarte, H. Isoniemi, P. Laakkonen, G. Christofori, S. Ylä-Herttuala, M. Shibuya, B. Pytowski, A. Eichmann, C. Betsholtz, K. Alitalo: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454, 656-660 (2008)
22. S. Sawamiphak, S. Seidel, CL. Essmann, G.A. Wilkinson, M.E. Pitulescu, T. Acker and A. Acker-Palmer: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 465, 487-491 (2010)
23. Y. Wang, M. Nakayama, M.E. Pitulescu, T.S. Schmidt, M.L. Bochenek, A. Sakakibara, S. Adams, A. Davy, U. Deutsch, U. Lüthi, A. Barberis, L.E. Benjamin, T. Mäkinen, C.D. Nobes and R.H. Adams: Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature 465, 483-486 (2010)
24. S.Y. Rabbany, B. Heissig, K. Hattori and S. Rafii: Molecular pathways regulating mobilization of marrowderived stem cells for tissue revascularization. Trends Mol Med 9, 109-117 (2003) (Pubitemid 36433892)
25. J. Holash, P.C. Maisonpierre, D. Compton, P. Boland, C.R. Alexander, D. Zagzag, G.D. Yancopoulos and S.J. Wiegand: Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284, 1994-1998 (1999) (Pubitemid 29309448)
26. R.S. Kerbel: A cancer therapy resistant to resistance. Nature 390, 335-336 (1997) (Pubitemid 28027292)
27. L.M. Ellis and D.J. Hicklin: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev Cancer 8, 579-591 (2008)
28. G. Bergers and D. Hanahan: Modes of resistance to anti-angiogenic therapy. Nature Rev Cancer 8, 592-603 (2008)
29. N. Ferrara: Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth factor Rev 21, 21-26 (2010)
30. O. Casanovas, D.J. Hicklin, G. Bergers and D. Hanahan: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005) (Pubitemid 41443415)
31. J. Glade Bender, E.M. Cooney, J.J. Kandel and D.J. Yamashiro: Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 7, 289-300 (2004) (Pubitemid 39469101)
32. L. Xu, D.G. Duda, E. di Tomaso, M. Ancukiewicz, D.C. Chung, G.Y. Lauwers, R. Samuel, P. Shellito, B.G. Czito, P.C. Lin, M. Poleski, R. Bentley, J.W. Clark, C.G. Willett and R.K. Jain: Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 69, 7905-7910 (2009)
33. D. Huang, Y. Ding, M. Zhou, B.I. Rini, D. Petillo, C.N. Qian, R. Kahnoski, P.A. Futreal, K.A. Furge and B.T. The: Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70, 1063-1071 (2010)
34. Y. Crawford, I. Kasman, L. Yu, C. Zhong, X. Wu, Z. Modrusan, J. Kaminker and N. Ferrara: PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15, 21-34 (2009)
35. G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland and D. Hanahan: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111, 1287-1295 (2003) (Pubitemid 36554699)
36. F. Shojaei, X. Wu, A.K. Malik, C. Zhong, M.E. Baldwin, S. Schanz, G. Fuh, H.P. Gerber and N. Ferrara: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25, 911-920 (2007) (Pubitemid 47236916)
37. J. Vandercappellen, J. Van Damme and S. Struyf: The role of CXC chemokines and their receptors in cancer. Cancer Lett 267, 226-244 (2008)
38. Y. Masuda, Y. Takatsu, Y. Terao, S. Kumano, Y. Ishibashi, M. Suenaga, M. Abe, S. Fukusumi, T. Watanabe, Y. Shintani, T. Yamada, S. Hinuma, N. Inatomi, T. Ohtaki, H. Onda and M. Fujino: Isolation and identification of EGVEGF/prokineticins as cognate ligands for two orphan Gprotein-coupled receptors. Biochem Biophys Res Commun 293, 396-402 (2002) (Pubitemid 34694220)
39. J. Haigh, J. McVeigh and P. Greer: The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the transgolgi network. Cell Growth Differ 7, 931-944 (1996) (Pubitemid 26360733)
40. N. Itoh and D.M. Ornitz: Evolution of the Fgf and Fgfr gene families. Trends Genet 20, 563-569 (2004) (Pubitemid 39314564)
41. P. Klint and L. Claesson-Welsh: Signal transduction by fibroblast growth factor receptors. Front Biosci 4, D165-177 (1999)
42. M. Rusnati and M. Presta: Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 13, 2025-2044 (2007) (Pubitemid 47040487)
43. D.M. Ornitz, J. Xu, J.S. Colvin, D.G. McEwen, C.A. MacArthur, F. Coulier, G. Gao and M. Goldfarb: Receptor specificity of the fibroblast growth factor family. J Biol Chem 271, 15292-15297 (1996) (Pubitemid 26195013)
44. S. Kanda, E. Landgren, M. Ljungström and L. Claesson-Welsh: Fibroblast growth factor receptor 1-induced differentiation of endothelial cell line established from tsA58 large T transgenic mice. Cell Growth Differ 7, 383-395 (1996) (Pubitemid 26360777)
45. T. Nakamura, Y. Mochizuki, H. Kanetake and S. Kanda: Signals via FGF receptor 2 regulate migration of endothelial cells. Biochem Biophys Res Commun 289, 801-806 (2001) (Pubitemid 34060074)
46. S. Ortega, M. Ittmann, S.H. Tsang, M. Ehrlich and C. Basilico: Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc Natl Acad Sci U S A 95, 5672-5677 (1998) (Pubitemid 28224154)
47. A. Montero, Y. Okada, M. Tomita, M. Ito, H. Tsurukami, T. Nakamura, T. Doetschman, J.D. Coffin and M.M. Hurley: Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 105, 1085-1093 (2000) (Pubitemid 30217693)
48. H. Xu, K.W. Lee and M. Goldfarb: Novel recognition motif on fibroblast growth factor receptor mediates direct association and activation of SNT adapter proteins. J Biol Chem 273, 17987-17990 (1998) (Pubitemid 28334707)
49. Y.R. Hadari, H. Kouhara, I. Lax and J. Schlessinger: Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol Cell Biol 18, 3966-3973 (1998) (Pubitemid 28287920)
50. S.H. Ong, Y.R. Hadari, N. Gotoh, G.R. Guy, J. Schlessinger and I. Lax: Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S A 98, 6074-6079 (2001) (Pubitemid 32488195)
51. S.H. Lee, D.J. Schoss, L. Jarvis, M.A. Krasnow and J.L. Swain: Inhibition of angiogenesis by a mouse sprouty protein. J Biol Chem 276, 4128-4133 (2001)
52. M.A. Impagnatiello, S. Weitzer, G. Gannon, A. Compagni, M. Cotten annd G. Christofori: Mammalian sprouty-1 and -2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol 152, 1087-1098 (2001) (Pubitemid 34286083)
53. M. Mohammadi, C.A. Dionne, W. Li, N. Li, T. Spivak, A.M. Honegger, M. Jaye and J. Schlessinger: Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis. Nature 358, 681-684 (1992)
54. K.G. Peters, J. Marie, E. Wilson, H.E. Ives, J. Escobedo, M. Del Rosario, D. Mirda and L.T. Williams: Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature 358, 678-681 (1992)
55. S. Javerzat, P. Auguste and A. Bikfalvi: The role of fibroblast growth factors in vascular development. Trends Mol Med 8, 483-489 (2002)
56. M.J. Cross and L. Claesson-Welsh: FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22, 201-207 (2001) (Pubitemid 32244307)
57. S. Kanda, E.C. Lerner, S. Tsuda, T. Shono, H. Kanetake and T.E. Smithgall: The nonreceptor proteintyrosine kinase c-Fes is involved in fibroblast growth factor-2-induced chemotaxis of murine brain capillary endothelial cells. J Biol Chem 275, 10105-10111 (2000) (Pubitemid 30202062)
58. S. Kanda, Y. Miyata, H. Kanetake and T.E. Smithgall: Fibroblast growth factor-2 induces the activation of Src through Fes, which regulates focal adhesion disassembly. Exp Cell Res 312, 3015-3022 (2006) (Pubitemid 44292659)
59. Y. Mochizuki, S. Tsuda, H. Kanetake and S. Kanda: Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase. Oncogene 21, 7027-7033 (2002) (Pubitemid 35252976)
60. S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand, J. Holash and G.D. Yancopoulos: Vascular-specific growth factors and blood vessel formation. Nature 407:242-248 (2000)
61. D.J. Dumont, G. Gradwohl, G.-H. Fong, M.C. Puri, M. Gertsenstein, A. Auerbach and M.L. Breitman: Dominantnegative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8, 1897-1909 (1994) (Pubitemid 24273890)
62. C. Suri, P.F. Jones, S. Patan, S. Bartunkova, P.C. Maisonpierre, S. Davis, T.N. Sato and G.D. Yancopoulos: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87, 1171-1180 (1996) (Pubitemid 27010101)
63. P.C. Maisonpierre, C. Suri, P.F. Jones, S. Bartunkova, S.J. Wiegand, C. Radziejewski, D. Compton, J. McClain, T.H. Aldrich, N. Papadopoulos, T.J. Daly, S. Davis, T.N. Sato and G.D. Yancopoulos: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277, 55-60 (1997) (Pubitemid 27450643)
64. I. Kim, J.-H. Kim, S.-O. Moon, H.J. Kwak, N.-G. Kim and G.Y. Koh: Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Oncogene 19, 4549-4552 (2000)
65. Y. Mochizuki, T. Nakamura, H. Kanetake and S. Kanda: Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J Cell Sci 115, 175-183 (2002) (Pubitemid 34105540)
66. N.W. Gale, G. Thurston, S.F. Hackett, R. Renard, Q. Wang, J. McClain, C. Martin, C. Witte, M.H. Witte, D. Jackson, C. Suri, P.A. Campochiaro, S.J. Wiegand and G.D. Yancopoulos: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3, 411-423 (2002)
67. S. Davis, N. Papadopoulos, T.H. Aldrich, P.C. Maisonpierre, T. Huang, L. Kovac, A. Xu, R. Leidich, E. Radziejewska, A. Rafique, J. Goldberg, V. Jain, K. Bailey, M. Karow, J. Fandl, S.J. Samuelsson, E. Ioffe, J.S. Rudge, T.J. Daly, C. Radziejewski and G.D. Yancopoulos: Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 10, 38-44 (2003) (Pubitemid 36034175)
68. S. Fukuhara, K. Sako, T. Minami, K. Noda, H.Z. Kim, T. Kodama, M. Shibuya, N. Takakura, G.Y. Koh and N. Mochizuki: Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol 10, 513-526 (2008) (Pubitemid 351627371)
69. P. Saharinen, L. Eklund, J. Miettinen, R. Wirkkala, A. Anisimov, M. Winderlich, A. Nottebaum, D. Vestweber, U. Deutsch, G.Y. Koh, B.R. Olsen and K. Alitalo: Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol 10, 527-537 (2008) (Pubitemid 351627372)
70. K.G. Peters, C.D. Kontos, P.C. Lin, A.L. Wong, P. Rao, L. Huang, M.W. Dewhirst and S. Sankar: Functional significance of Tie2 signaling in the adult vasculature. Recent Prog Horm Res 59, 51-71 (2004)
71. T. Etoh, H. Inoue, S. Tanaka, G.F. Barnard, S. Kitano and M. Mori: Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. Cancer Res 61, 2145-2153 (2001) (Pubitemid 32692040)
72. W.S. Shim, M. Teh, A. Bapna, I. Kim, G.Y. Koh, P.O. Mack and R. Ge: Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res 279, 299-309 (2002) (Pubitemid 35217558)
73. T. Nakayama, L. Yao and G. Tosato: Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. J Clin Invest 114, 1317-1325 (2004) (Pubitemid 40385303)
74. M.R. Machein, A. Knedla, R. Knoth, S. Wagner, E. Neuschl and K.H. Plate: Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 165, 1557-1570 (2004) (Pubitemid 39435155)
75. R. Maffei, S. Martinelli, I. Castelli, R. Santachiara, P. Zucchini, M. Fontana, S. Fiorcari, G. Bonacorsi, F. Ilariucci, G. Torelli and R. Marasca: Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk Res 34, 312-321 (2010)
76. K.M. Detjen, S. Rieke, A. Deters, P. Schulz, A. Rexin, S. Vollmer, P. Hauff, B. Wiedenmann, M. Pavel and A. Scholz: Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 16, 420-429 (2010)
77. J. Oliner, H. Min, J. Leal, D. Yu, S. Rao, E. You, X. Tang, H. Kim, S. Meyer, S.J. Han, N. Hawkins, R. Rosenfeld, E. Davy, K. Graham, F. Jacobsen, S. Stevenson, J. Ho, Q. Chen, T. Hartmann, M. Michaels, M. Kelley, L. Li, K. Sitney, F. Martin, J.R. Sun, N. Zhang, J. Lu, J. Estrada, R. Kumar, A. Coxon, S. Kaufman, J. Pretorius, S. Scully, R. Cattley, M. Payton, S. Coats, L. Nguyen, B. Desilva, A. Ndifor, I. Hayward, R. Radinsky, T. Boone and R. Kendall: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 6, 507-516 (2004) (Pubitemid 39469986)
78. H. Hashizume, B.L. Falcón, T. Kuroda, P. Baluk, A. Coxon, D. Yu, J.V. Bready, J.D. Oliner and D.M. McDonald: Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70, 2213-2223 (2010)
79. A.C. Mita, C.H. Takimoto, M. Mita, A. Tolcher, K. Sankhala, J. Sarantopoulos, M. Valdivieso, L. Wood, E. Rasmussen, Y.N. Sun, Z.D. Zhong, M.B. Bass, N. Le and P. Lorusso: Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors. Clin Cancer Res 16, 3044-3056 (2010)
80. S. Kanda, Y. Miyata, Y. Mochizuki, T. Matsuyama and H. Kanetake: Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res 65, 6820-6827 (2005) (Pubitemid 41060720)
81. N. Jones and D.J. Dumont: Tek/Tie2 signaling: new and old partners. Cancer Metastasis Rev 19, 13-17 (2000) (Pubitemid 32004687)
82. R. Salcedo, K. Wasserman, H.A. Young, M.C. Grimm, O.M. Howard, M.R. Anver, H.K. Kleinman, W.J. Murphy and J.J. Oppenheim: Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. Am J Pathol 154, 1125-1135 (1999) (Pubitemid 29169747)
83. K. Tachibana, S. Hirota, H. Iizasa, H. Yoshida, K. Kawabata, Y. Kataoka, Y. Kitamura, K. Matsushima, N. Yoshida, S. Nishikawa, T. Kishimoto and T. Nagasawa: The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393, 591-594 (1998) (Pubitemid 28319250)
84. I. Petit, D. Jin and S. Rafii: The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trend Immunol 28. 299-307 (2007) (Pubitemid 46963141)
85. A. Schober, S. Knarren, M. Lietz, E.A. Lin and C. Weber: Crucial role of stromal cell-derived factor-1alpha in neointima formation after vascular injury in apolipoprotein E-deficient mice. Circulation 108, 2491-2497 (2003) (Pubitemid 37444411)
86. J.B. Rubin: Chemokine signaling in cancer: one hump or two? Sem Cancer Biol 19, 116-122 (2009)
87. A.J. Vila-Colo, J.M. Rodriguez-Frade, A.M. De Ana, M.C. Moreno-Ortiz, C. Martinez-A and M. Mellado: The chemokine SDF-1 triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 13, 1699-1710 (1999) (Pubitemid 29473332)
88. M. Moriguchi, B.D. Hissong, M. Gadina, K. Yamaoka, H.L. Tiffany, P.M. Murphy, F. Candotti and J.J. O'Shea: CXCL12 signaling is independent of Jak2 and Jak3. J Biol Chem 280, 17408-17414 (2005) (Pubitemid 41389211)
89. L. Stephens, A. Smrcka, F.T. Cooke, T.R. Jackson, P.C. Sternweis and P.T. Hawkins: A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein beta gamma subunits. Cell 77, 83-93 (1994) (Pubitemid 24184690)
90. T. van Biesen, B.E. Hawes, D.K. Luttrell, K.M. Krueger, K. Touhara, E. Porfiri, M. Sakaue, L.M. Luttrell and R.J. Lefkowitz: Receptor-tyrosine-kinase- and G beta gamma-mediated MAP kinase activation by a common signalling pathway. Nature 376, 781-784 (1995)
91. S. Kanda, Y. Mochizuki and H. Kanetake: Stromal cellderived factor-1alpha induces tube-like structure formation of endothelial cells through phosphoinositide 3-kinase. J Biol Chem 278, 257-262 (2003) (Pubitemid 36043570)
92. M. Graupera, J. Guillermet-Guibert, L.C. Foukas, L.K. Phng, R.J. Cain, A. Salpekar, W. Pearce, S. Meek, J. Millan, P.R. Cutillas, A.J. Smith, A.J. Ridley, C. Ruhrberg, H. Gerhardt and B. Vanhaesebroeck: Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453, 662-666 (2008) (Pubitemid 351769296)
93. D.J. Waugh and C. Wilson: The interleukin-8 pathway in cancer. Clin Cancer Res 14, 6735-6741 (2008)
94. G. Venkatakrishnan, R. Salgia and J.E. Groopman: Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 275, 6868-6875 (2000) (Pubitemid 30146227)
95. I.U. Schraufstatter, K. Trieu, M. Zhao, D.M. Rose, R.A. Terkeltaub and M. Burger: IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J Immunol 171, 6714-6722 (2003) (Pubitemid 37532104)
96. F. Luppi, A.M. Longo, W.I. de Boer, K.F. Rabe and P.S. Hiemstra: Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 56, 25-33 (2007) (Pubitemid 46356635)
97. M.L. Petreaca, M. Yao, Y. Lui, K. Defea and M. Martins-Green: Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 18, 5014-5023 (2007) (Pubitemid 350246701)
98. S. Kanda, A. Naba and Y. Miyata: Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity. Int J Oncol 35, 1305-1312 (2009)
99. S. Kanda, Y. Mochizuki, Y. Miyata and H. Kanetake: The role of c-Fes in vascular endothelial growth factor-Amediated signaling by endothelial cells. Biochem Biophys Res Commun 306, 1056-1063 (2003) (Pubitemid 36776238)
100. N. Ferrara, K. Carver Moore, H. Chen, M. Dowd, L. Lu, K.S. O'Shea, L. Powell Braxton, K.J. Hillan and M.W. Moore: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439-442 (1996) (Pubitemid 26102720)
101. P. Carmeliet, V. Ferreira, G. Breier, S. Pollefeyt, L. Kieckens, M. Gertsenstein, M. Fahrig, A. Vandenhoeck, H. Kendraprasad, C. Eberhardt, C. Declercq, J. Pawling, L. Moons, D. Collen, W. Risau and A. Nagy: Abnormal blood vessel development and lethality in embryos lacking a single vascular endothelial growth factor allele. Nature 380, 435-439 (1996) (Pubitemid 26102719)
102. F. Shalaby, J. Rossant, T.P. Yamaguchi, M. Gertsenstein, X.F. Wu, M.L. Breitman and A.C. Schuh: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66 (1995)
103. J.J. Haigh, M. Ema, K. Haigh, M. Gertsenstein, P. Greer, J. Rossant, A. Nagy and E.F. Wagner EF: Activated Fps/Fes partially rescues the in vivo developmental potential of Flk1-deficient vascular progenitor cells. Blood 103, 912-920 (2004) (Pubitemid 38129550)
104. W. Sangrar, J.D. Mewburn, S.G. Vincent, J.T. Fisher and P.A. Greer: Vascular defects in gain-of-function fps/fes transgenic mice correlate with PDGF- and VEGF-induced activation of mutant Fps/Fes kinase in endothelial cells. J Thromb Haemost 2, 820-832 (2004) (Pubitemid 40185720)
105. S.J. Wang, P. Greer and R. Auerbach: Isolation and propagation of yolk-sac-derived endothelial cells from a hypervascular transgenic mouse expressing gain-offunction fps/fes protooncogene. In vitro Cell Dev Biol Anim 32, 292-299 (1996)
106. S. Kanda, H. Kanetake and Y. Miyata: Downregulation of Fes inhibits VEGF-A-induced chemotaxis and capillary-like morphogenesis by cultured endothelial cells. J Cell Mol Med 11, 495-501 (2007) (Pubitemid 47153459)
107. S. Kanda, Y. Miyata and H. Kanetake: Role of focal adhesion formation in migration and morphogenesis of endothelial cells. Cell Signal 16, 1273-1281 (2004) (Pubitemid 39165455)
108. Y. Senis, R. Zirngibl, J. McVeigh, A. Haman, T. Hoang T and P.A. Greer: Targeted disruption of the murine fps/fes proto-oncogene reveals that Fps/Fes kinase activity is dispensable for hematopoiesis. Mol Cell Biol 19, 7436-7446 (1999) (Pubitemid 29493407)
109. R. Hackenmiller, J. Kim, R.A. Feldman and M.C. Simon: Abnormal Stat activation, hematopoietic homeostasis, and innate immunity in c-fes-/- mice. Immunity 13, 397-407 (2000)
110. R.A. Zirngibl, Y. Senis and P.A. Greer: Enhanced endotoxin sensitivity in fps/fes-null mice with minimal defects in hematopoietic homeostasis. Mol Cell Biol 22, 2472-2486 (2002) (Pubitemid 34262970)
111. P. Greer, J. Haigh, G. Mbamalu, W. Khoo, A. Bernstein and T. Pawson: The Fps/Fes protein-tyrosine kinase promotes angiogenesis in transgenic mice. Mol Cell Biol 14, 6755-6763 (1994) (Pubitemid 24299745)
112. M. Grunewald, I. Avraham, Y. Dor, E. Bachar-Lustig, A. Itin, S. Jung, S. Chimenti, L. Landsman, R. Abramovitch and E. Keshet: VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124, 175-189 (2006) (Pubitemid 43069318)
113. A. Orimo, P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson and R.A. Weinberg: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005) (Pubitemid 40692295)
114. C. Murdoch, S. Tazzyman, S. Webster and C.E. Lewis: Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol 178, 7405-7411 (2007) (Pubitemid 46847468)
115. M. De Palma, M.A. Venneri, R. Galli, L. Sergi Sergi, L.S. Politi, M. Sampaolesi and L. Naldini: Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8, 211-226 (2005) (Pubitemid 41317592)
116. A. Mantovani, P. Allavena, A. Sica and F. Balkwill: Cancer-related inflammation. Nature 454, 436-444 (2008)
117. C. Lewis C and C. Murdoch: Macrophage responses to hypoxia: implications for tumor progression and anticancer therapies. Am J Pathol 167, 627-635 (2005) (Pubitemid 41216349)
118. F. Shojaei, X. Wu, C. Zhong, L. Yu, X.H. Liang, J. Yao, D. Blanchard, C. Bais, F.V. Peale, N. van Bruggen, C. Ho, J. Ross, M. Tan, R.A. Carano, Y.G. Meng and N. Ferrara: Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831 (2007) (Pubitemid 350231321)